谭张龙

[摘要] 目的 研究咪唑斯汀和雷尼替丁联合治疗慢性特发性荨麻疹的疗效和安全性。方法 方便选取该院2015年2月—2016年6月期间收治的80例慢性特发性荨麻疹患者作为研究对象，将其随机分为对照组和观察组，每组40例。对照组单一采用咪唑斯汀进行治疗，观察组在对照组基础上联合雷尼替丁进行治疗。对比两组疗效和不良反应发生率。 结果 治疗结束后，两组症状评分均明显下降（P<0.05），观察组下降（1.33±0.27）分，对照组下降（0.83±0.18）分，观察组评分下降幅度显著优于对照组（P<0.05）；观察组有效率为97.5%，对照组有效率为80.0%，观察组疗效远优于对照组，治疗有效率对比差异有统计学意义 （P<0.05）；观察组不良反应率为5.0%，对照组为27.5%，两组患者在不良反应发生率方面对比差异无统计学意义（P>0.05）。结论 在治疗慢性特发性荨麻疹的过程中，采用咪唑斯汀联合雷尼替丁治疗方法具有更好效果，在安全性方面也更具优势，建议推广至临床。

[关键词] 咪唑斯汀；雷尼替丁；慢性特发性荨麻疹；疗效；不良反应

[中图分类号] R758 [文献标识码] A [文章编号] 1674-0742（2017）05（a）-0148-03

[Abstract] Objective Objective to study the efficacy and safety of mizolastine and ranitidine in the treatment of chronic idiopathic urticaria. Methods Methods 80 cases of patients with chronic idiopathic urticaria admitted in our hospital from February 2015 to June 2016 were randomly divided into control group and observation group， each group had a total of 40 cases. The control group was treated with mizolastine， while the observation group was treated with ranitidine on the basis of the control group. The efficacy and adverse reactions were compared between the two groups. Results After the end of treatment， two groups of symptom scores were significantly decreased （P<0.05），the observation group decreased （1.33±0.27）scores，control group （0.83±0.18）scores， the observation group were decreased significantly than the control group （P<0.05）； observation group was 97.5%，the control group was 80.0%.The effect of observation group is much better than that of the control group，the effective rate of the treatment compared with statistical difference （P<0.05）；adverse reaction rate of the observation group was 5.0%，control group 27.5%，two groups of patients the incidence of contrast does not exist significant differences in adverse reactions （P>0.05）.Conclusion In the treatment of chronic idiopathic urticaria， the combination of mizolastine and ranitidine has a better effect， and has more advantages in safety.

[Key words] Mizolastine；Ranitidine；Chronic idiopathic urticaria；Curative effect；Adverse reaction

慢性特发性荨麻疹（CIU）是临床中非常常见的过敏性皮肤疾病，其风团伴瘙痒症状几乎每天都会出现，并且会持续长达至少6周时间[1]。目前对于导致慢性特发性荨麻疹的原因还不清楚，并且长期以来在治疗慢性特发性荨麻疹疾病方面疗效不佳[2]。很多时候，患者自身的问题才是导致疗效不理想的重要因素，而这样的情况会严重影响患者的生活质量。过去在治疗慢性特发性荨麻疹时，通常采用的是口服组胺H1受体拮抗剂治疗措施，而现在认为，联合使用H1和H2受体拮抗剂的疗效良好[3]。为研究咪唑斯汀与雷尼替丁治疗慢性特发性荨麻疹方面的疗效和不良反应率，方便选取该院2015年2月—2016年6月收治的80例慢性特发性荨麻疹患者进行对比研究，现报道如下。……